LNAI News & Events

Lunai Bioworks and Geneial, a precision medicine data infrastructure and patient engagement company, announced that BioSymetrics, a wholly owned Lunai subsidiary, has signed a Letter of Intent, or LOI, with Geneial to pursue a strategic collaboration in rare neurological disorders. The collaboration is designed to support rare disease research and advocacy groups in converting fragmented, patient-generated data into actionable drug development programs, including the creation and activation of trial-ready patient cohorts that can support pharmaceutical partnerships. Under the proposed collaboration, BioSymetrics and Geneial plan to: integrate and standardize patient-led rare disease datasets; identify defined patient subgroups for clinical development; generate actionable insights to support therapeutic programs; enable the activation of trial-ready cohorts for pharma and biotech engagement. The companies expect to pursue commercial partnerships enabled by these efforts. The initial focus will include select rare neurodevelopmental disorders, with the goal of building scalable programs that can expand over time. The LOI is non-binding.

Lunai Bioworks has executed a binding $20M strategic transaction to acquire blood-brain barrier, or BBB, delivery technology and central nervous system, or CNS, Alzheimer's drug assets from the Clemann Group, SAS or its assignee. The transaction is structured as Series B Convertible Preferred at a fixed conversion price of $1.50 per share, subject to a 19.9% beneficial ownership limitation. The transaction aims to strengthen Lunai's CNS Alzheimer's pipeline by pairing biological target identification with a proven delivery method and expand the company's ability to develop next-generation treatments across a broad range of CNS disorders where traditional drugs struggle to penetrate the brain effectively, offering the potential for improved safety and efficacy.